Researchers Identified Antibodies That Target Alpha-Gal
New findings offer a potential future pathway for managing alpha-gal syndrome in affected patients.
Updated on Sept. 28, 2026 in Allergies
Live Poll
Does new research on antibody-based treatments increase your trust in the future management of allergies?
Researchers identified two monoclonal antibodies that successfully block IgE binding to alpha-gal allergens in laboratory tests. This development could eventually lead to new treatments for alpha-gal syndrome, a condition that has seen 110,000 suspected cases in the U.S. since 2010.
Why it matters
Currently, no disease-modifying therapy exists for alpha-gal syndrome, leaving patients to rely on strict avoidance of red meat and other products. This research creates a new potential avenue for therapeutic intervention for the thousands of Americans managing the allergy.
In a laboratory study, investigators screened 42 human monoclonal antibodies, finding that two specific candidates—AG028 and AG050—inhibited IgE binding to major alpha-gal allergens by 60% to 97%. These preliminary results demonstrate that the antibodies can block basophil activation.
The players
NIAID
The National Institute of Allergy and Infectious Diseases is a federal agency that conducts research into immunology and allergic conditions.
The details
The antibodies were generated using B cells harvested from malaria-exposed donors. By targeting the alpha-gal sugar molecule, these antibodies prevent IgE—the immune protein responsible for allergic reactions—from binding to the allergen and triggering the release of inflammatory chemicals from basophils. When preincubated with soluble alpha-gal, the antibodies' ability to bind was abolished, confirming their specificity to the target.
Timeline
2010 marked the start of alpha-gal syndrome case tracking in the United States.
Health Landscape
This development represents a departure from traditional symptom management for alpha-gal syndrome, which currently relies entirely on dietary avoidance. The work extends the scope of the NIAID alpha-gal research program by moving toward potential targeted immunotherapy.
This study is a preliminary laboratory finding and does not change current care, but it underscores the importance of consulting with an allergist to confirm an alpha-gal diagnosis. Anyone managing this condition should continue to follow their physician-guided avoidance plan until new treatments are approved.
The takeaway
While this laboratory research into monoclonal antibodies is promising, it is not yet a treatment for human use. Patients should continue to prioritize strict adherence to their current medically-supervised diet and discuss any new potential therapy research with their allergist.
Further reading
Learn more about the latest research and management strategies for Allergies.
Source note: This article includes information reported by Hcplive.
Live Poll
Does new research on antibody-based treatments increase your trust in the future management of allergies?
